Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction

Journal of the American College of Cardiology

Volumn 33, Issue 1, 1999, Pages 119-124

  Garratt, Kirk N ^a,b   Brady, Peter A ^b   Hassinger, Nancy L ^a   Grill, Diane E ^a   Terzic, Andre ^a   Holmes Jr , David R ^a  

^a MAYO CLINIC   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLYCERYL TRINITRATE; HEPARIN; SULFONYLUREA DERIVATIVE;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DIABETES MELLITUS; DRUG USE; FEMALE; HEART EJECTION FRACTION; HEART VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMIC PROCESSES; HOSPITAL MORTALITY; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; REGRESSION ANALYSIS; RISK; SULFONYLUREA COMPOUNDS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032895997     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00557-9     Document Type: Article

References (46)

1. Mak KH, Moliterno DJ, Granger CB, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. J Am Coll Cardiol 1997;30:171-9.
2. Abbud ZA, Shindler DM, Wilson AC, Kostis JB. Effect of diabetes mellitus on short- and long-term mortality rates of patients with acute myocardial infarction: a statewide study. Myocardial Infarction Data Acquisition System Study Group. Am Heart J 1995;130:51-8.
3. Malmberg K, Ryden L. Myocardial infarction in patients with diabetes mellitus. Eur Heart J 1988;9:259-64.
4. BARI Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217-25.
5. Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995;91:979-89.
6. Rytter L, Troelsen S, Beck-Nielsen H. Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care 1985;8:230-4.
7. Klimt CR, Knatterud GL, Meinert CL, Prout TE. A study of the effects of hypoglycemic agents in vascular complications in patients with adult-onset diabetes. Diabetes 1970;19:747-830.
8. Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol 1998;31:950-6.
9. Panten U, Schwanstecher M, Schwanstecher C. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp Clin Endocrinol Diabetes 1996;104: 1-9.
10. Groop L. Sulphonylureas in NIDDM. Diabetes Care 1992;15:737-54.
11. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989;321:1231-45.
12. Edwards G, Weston A. The pharmacology of ATP-sensitive potassium channels. Annu Rev Pharmacol Toxicol 1993;33:597-637.
13. Ashcroft SJ, Ashcroft FM. The sulphonylurea receptor. Biochim Biophys Acta 1992;1175:45-59.
14. + channels: regulation by intracellular nucleotides and potassium opening drugs. Am J Physiol 1995;38:C525-45.
15. + channel current in atrial myocytes of guinea pig heart. Jpn J Pharmacol 1990;54:473-7.
16. + channels in cardiac muscle by the sulphonylurea drug glibenclamide. J Pharmacol Exp Ther 1992;261:540-5.
17. + channels. J Biol Chem 1988;263:7933-6.
18. Cleveland JC Jr, Meldrum DR, Cain BS, Banerjee A, Harkem AH. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium: two paradoxes revisited. Circulation 1997;96:29-32.
19. Grover GJ. Protective effects of ATP-sensitive potassium-channel openers in experimental myocardial ischemia. J Cardiovasc Pharmacol 1994;24:S18-27.
20. Gross GJ. ATP-sensitive potassium channels and myocardial preconditioning. Basic Res Cardiol 1995;90:85-8.
21. ATP channels and nitric oxide in conscious dogs. Circulation 1996;95:1568-76.
22. Jackson WF. Arteriolar tone is determined by activity of ATP-sensitive potassium channels. Am J Physiol 1993;265:H1797-803.
23. Narishige T, Egashira K, Akatsuka Y, Takahashi T, Kasuya H, Takeshita A. Glibenclamide prevents coronary vasodilation induced by β1-adrenoceptor stimulation in dogs. Am J Physiol 1994;266:H84-92.
24. Murray C, Jennings R, Reimer K. Preconditioning with ischemia: a delay in lethal injury in ischaemic myocardium. Circulation 1986;74:1124-36.
25. ATP blockade in type II diabetes and preconditioning in cardiovascular disease: time for reconsideration. Circulation 1996;94:2297-301.
26. + channel blocker. Circulation 1994;90:700-5.
27. 2+ loading in cardiomyocytes. Eur J Pharmacol 1996;308:343-9.
28. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992;70:223-33.
29. O'Murchu B, Gersh BJ, Reeder GS, Bailey KR, Holmes DR Jr. Late outcome after percutaneous transluminal coronary angioplasty during acute myocardial infarction. Am J Cardiol 1993;72:634-9.
30. Zaret BL, Wackers FJ, Terrin ML, et al. Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) phase II study. The TIMI Study Group. J Am Coll Cardiol 1995;26:73-9.
31. Heine RJ. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II-"The cons." Horm Metab Res 1996;28:522-6.
32. Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 1996;28:371-80.
33. Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation 1994;89:321-30.
34. Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995;91:764-70.
35. Morishita E, Asakura H, Jokaji H, et al. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. Atherosclerosis 1996;120:7-14.
36. Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995;74:842-7.
37. Ito Y, Okeda T, Sato Y, Ito M, Sakata T. Plasminogen activator inhibitor-1 in nonobese subjects with non-insulin-dependent diabetes mellitus. Proc Soc Exp Biol Med 1996;211:287-91.
38. Gray RP, Yudkin JS, Patterson DL. Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor? Br Heart J 1993;70:530-6.
39. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994;43:104-9.
40. Testa R, Bonfigli AR, Piantanelli L, Manfrini S, Testa I, Gregorio F. Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1996;33:111-8.
41. Hasdai D, Garratt KN, Holmes DR Jr, Berger PB, Schwartz RS, Bell MR. Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis. J Am Coll Cardiol 1996;28:361-7.
42. Ambrose JA, Weinrauch M. Thrombosis in ischemic heart disease. Arch Intern Med 1996;156:1382-94.
43. Oltrona L, Eisenberg PR, Lasala JM, Sewall DJ, Shelton ME, Winters KJ. Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. Circulation 1996;94:2064-71.
44. Brady PA, Al-Suwaidi J, Kopecky SL, Terzic A. Sulphonylureas and mortality in diabetic patients with myocardial infarction. Circulation 1998; 97:709-10.
45. ATP channels. Am J Physiol 1996;271:H2710-6.
46. ATP channels towards sulfonylureas. Circ Res 1998;82:272-8.